Information Provided By:
Fly News Breaks for January 19, 2018
CYTK
Jan 19, 2018 | 07:14 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $20 after spending time with management. CK-107 could be the molecule that resets the investment thesis in 2018, Pantginis tells investors in a research note. The analyst looks for a "quick turnaround" in 2018 and keeps a Buy rating on the shares.
News For CYTK From the Last 2 Days
There are no results for your query CYTK